Bernstein Initiates Coverage on Amgen(NASDAQ:AMGN). The shares have been rated Market Perform. The rating by Bernstein was issued on Jun 29, 2016.
In a different note, BMO Capital said it Initiates Coverage on Amgen, according to a research note issued on Apr 5, 2016. The shares have been rated ‘Outperform’ by the firm.
Amgen (AMGN) made into the market gainers list on Fridays trading session with the shares advancing 1.40% or 2.13 points. Due to strong positive momentum, the stock ended at $154.28, which is also near the day’s high of $154.95. The stock began the session at $152.43 and the volume stood at 27,58,071 shares. The 52-week high of the shares is $181.81 and the 52 week low is $130.09. The company has a current market capitalization of $115,898 M and it has 75,12,17,080 shares in outstanding.
Amgen(AMGN) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $5.53B. Analysts had an estimated revenue of $5.32B. Earnings per share were $2.90. Analysts had estimated an EPS of $2.60.
Several Insider Transactions has been reported to the SEC. On May 5, 2016, Madhavan Balachandran (EVP, Operations) sold 30,000 shares at $154.12 per share price.Also, On May 3, 2016, Sean E Harper (EVP, Research & Development) sold 21,875 shares at $157.99 per share price.On May 3, 2016, David Baltimore (director) sold 3,312 shares at $157.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.